Year |
Citation |
Score |
2023 |
Marquardt V, Theruvath J, Pauck D, Picard D, Qin N, Blümel L, Maue M, Bartl J, Ahmadov U, Langini M, Meyer FD, Cole A, Cruz-Cruz J, Graef CM, Wölfl M, ... ... Mitra S, et al. Tacedinaline (CI-994), a class I HDAC inhibitor, targets intrinsic tumor growth and leptomeningeal dissemination in MYC-driven medulloblastoma while making them susceptible to anti-CD47-induced macrophage phagocytosis via NF-kB-TGM2 driven tumor inflammation. Journal For Immunotherapy of Cancer. 11. PMID 36639156 DOI: 10.1136/jitc-2022-005871 |
0.74 |
|
2022 |
Alimova I, Wang D, Danis E, Pierce A, Donson A, Serkova N, Madhavan K, Lakshmanachetty S, Balakrishnan I, Foreman NK, Mitra S, Venkataraman S, Vibhakar R. Targeting the TP53/MDM2 axis enhances radiation sensitivity in atypical teratoid rhabdoid tumors. International Journal of Oncology. 60. PMID 35179215 DOI: 10.3892/ijo.2022.5322 |
0.302 |
|
2021 |
Lakshmanachetty S, Cruz-Cruz J, Hoffmeyer E, Cole AP, Mitra SS. New Insights into the Multifaceted Role of Myeloid-Derived Suppressor Cells (MDSCs) in High-Grade Gliomas: From Metabolic Reprograming, Immunosuppression, and Therapeutic Resistance to Current Strategies for Targeting MDSCs. Cells. 10. PMID 33919732 DOI: 10.3390/cells10040893 |
0.66 |
|
2020 |
Cole AP, Hoffmeyer E, Chetty SL, Cruz-Cruz J, Hamrick F, Youssef O, Cheshier S, Mitra SS. Microglia in the Brain Tumor Microenvironment. Advances in Experimental Medicine and Biology. 1273: 197-208. PMID 33119883 DOI: 10.1007/978-3-030-49270-0_11 |
0.787 |
|
2020 |
Theruvath J, Sotillo E, Mount CW, Graef CM, Delaidelli A, Heitzeneder S, Labanieh L, Dhingra S, Leruste A, Majzner RG, Xu P, Mueller S, Yecies DW, Finetti MA, Williamson D, ... ... Mitra SS, et al. Locoregionally administered B7-H3-targeted CAR T cells for treatment of atypical teratoid/rhabdoid tumors. Nature Medicine. PMID 32341579 DOI: 10.1038/S41591-020-0821-8 |
0.632 |
|
2019 |
Gholamin S, Youssef OA, Rafat M, Esparza R, Kahn S, Shahin M, Giaccia AJ, Graves EE, Weissman I, Mitra S, Cheshier SH. Irradiation or temozolomide chemotherapy enhances anti-CD47 treatment of glioblastoma. Innate Immunity. 1753425919876690. PMID 31547758 DOI: 10.1177/1753425919876690 |
0.77 |
|
2019 |
SoRelle ED, Yecies DW, Liba O, Bennett FC, Graef CM, Dutta R, Mitra S, Joubert LM, Cheshier S, Grant GA, de la Zerda A. Spatiotemporal Tracking of Brain-Tumor-Associated Myeloid Cells in Vivo through Optical Coherence Tomography with Plasmonic Labeling and Speckle Modulation. Acs Nano. PMID 31259527 DOI: 10.1021/Acsnano.9B02656 |
0.629 |
|
2019 |
Mohanty S, Yerneni K, Theruvath JL, Graef CM, Nejadnik H, Lenkov O, Pisani L, Rosenberg J, Mitra S, Cordero AS, Cheshier S, Daldrup-Link HE. Nanoparticle enhanced MRI can monitor macrophage response to CD47 mAb immunotherapy in osteosarcoma. Cell Death & Disease. 10: 36. PMID 30674867 DOI: 10.1038/S41419-018-1285-3 |
0.609 |
|
2019 |
Majzner RG, Theruvath JL, Nellan A, Heitzeneder S, Cui Y, Mount CW, Rietberg SP, Linde MH, Xu P, Rota C, Sotillo E, Labanieh L, Lee DW, Orentas RJ, Dimitrov DS, ... ... Mitra SS, et al. CAR T cells targeting B7-H3, a Pan-Cancer Antigen, Demonstrate Potent Preclinical Activity Against Pediatric Solid Tumors and Brain Tumors. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 30655315 DOI: 10.1158/1078-0432.Ccr-18-0432 |
0.448 |
|
2019 |
Hutter G, Theruvath J, Graef CM, Zhang M, Schoen MK, Manz EM, Bennett ML, Olson A, Azad TD, Sinha R, Chan C, Assad Kahn S, Gholamin S, Wilson C, Grant G, ... ... Mitra SS, et al. Microglia are effector cells of CD47-SIRPα antiphagocytic axis disruption against glioblastoma. Proceedings of the National Academy of Sciences of the United States of America. PMID 30602457 DOI: 10.1073/Pnas.1721434116 |
0.798 |
|
2018 |
Kahn SA, Wang X, Nitta RT, Gholamin S, Theruvath J, Hutter G, Azad TD, Wadi L, Bolin S, Ramaswamy V, Esparza R, Liu KW, Edwards M, Swartling FJ, Sahoo D, ... ... Mitra SS, et al. Publisher Correction: Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nature Communications. 9: 4651. PMID 30389946 DOI: 10.1038/S41467-018-07182-1 |
0.747 |
|
2018 |
Bakhshinyan D, Venugopal C, Adile AA, Garg N, Manoranjan B, Hallett R, Wang X, Mahendram S, Vora P, Vijayakumar T, Subapanditha M, Singh M, Kameda-Smith MM, Qazi M, McFarlane N, ... ... Mitra S, et al. BMI1 is a therapeutic target in recurrent medulloblastoma. Oncogene. PMID 30348991 DOI: 10.1038/S41388-018-0549-9 |
0.443 |
|
2018 |
Kahn SA, Wang X, Nitta RT, Gholamin S, Theruvath J, Hutter G, Azad TD, Wadi L, Bolin S, Ramaswamy V, Esparza R, Liu KW, Edwards M, Swartling FJ, Sahoo D, ... ... Mitra SS, et al. Notch1 regulates the initiation of metastasis and self-renewal of Group 3 medulloblastoma. Nature Communications. 9: 4121. PMID 30297829 DOI: 10.1038/S41467-018-06564-9 |
0.784 |
|
2018 |
Garzia L, Kijima N, Morrissy AS, De Antonellis P, Guerreiro-Stucklin A, Holgado BL, Wu X, Wang X, Parsons M, Zayne K, Manno A, Kuzan-Fischer C, Nor C, Donovan LK, Liu J, ... ... Mitra S, et al. A Hematogenous Route for Medulloblastoma Leptomeningeal Metastases. Cell. 172: 1050-1062.e14. PMID 29474906 DOI: 10.1016/J.Cell.2018.01.038 |
0.414 |
|
2018 |
Mitra S, Cheshier S. IMMU-14. KICKSTARTING THE CANCER IMMUNITY CYCLE BY INNATE CHECKPOINT INHIBITION TO TARGET PEDIATRIC BRAIN TUMORS Neuro-Oncology. 20: i101-i101. DOI: 10.1093/Neuonc/Noy059.330 |
0.619 |
|
2018 |
Theruvath J, Graef C, Heitzeneder S, Majzner R, Mitra S, Cheshier SH, Mackall C. ATRT-25. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON ATYPICAL RHABDOID TERATOID TUMOR (ATRT) AND IS A PROMISING CANDIDATE FOR CAR T CELL THERAPY Neuro-Oncology. 20: i33-i33. DOI: 10.1093/Neuonc/Noy059.023 |
0.609 |
|
2017 |
Gholamin S, Mitra SS, Feroze AH, Liu J, Kahn SA, Zhang M, Esparza R, Richard C, Ramaswamy V, Remke M, Volkmer AK, Willingham S, Ponnuswami A, McCarty A, Lovelace P, et al. Disrupting the CD47-SIRPα anti-phagocytic axis by a humanized anti-CD47 antibody is an efficacious treatment for malignant pediatric brain tumors. Science Translational Medicine. 9. PMID 28298418 DOI: 10.1126/Scitranslmed.Aaf2968 |
0.804 |
|
2017 |
Zhu H, Leiss L, Yang N, Rygh CB, Mitra SS, Cheshier SH, Weissman IL, Huang B, Miletic H, Bjerkvig R, Enger PØ, Li X, Wang J. Surgical debulking promotes recruitment of macrophages and triggers glioblastoma phagocytosis in combination with CD47 blocking immunotherapy. Oncotarget. PMID 28076333 DOI: 10.18632/Oncotarget.14553 |
0.697 |
|
2017 |
Yu H, Truong H, Mitchell SA, Gosink JJ, Lin J, Feng JY, Jürgensmeier JM, Billin AN, Xu R, Mitra S. Abstract 4016: Homogeneous BTK occupancy assay for pharmacodynamic assessment of GS-4059 target engagement Cancer Research. 77: 4016-4016. DOI: 10.1158/1538-7445.Am2017-4016 |
0.337 |
|
2017 |
Chow K(, Heitzeneder S, Xu P, Theruvath J, Mitra SS, Cheshier SH, Li G, Mackall C. 327 B7-H3 Chimeric Antigen Receptor Modified T Cells Show Potent Anti-Tumor Activity in a Preclinical Model of Glioblastoma Neurosurgery. 64: 272-272. DOI: 10.1093/Neuros/Nyx417.327 |
0.62 |
|
2017 |
Hutter G, Theruvath J, Graef CM, Weissman I, Mitra SS, Cheshier SH. TMIC-04. A POTENT MICROGLIAL RESPONSE TO BLOCKING THE CD47-SIRPα ANTI-PHAGOCYTIC AXIS OVERCOMES DEFICIENT MACROPHAGE RECRUITMENT DURING ANTI-CD47 IMMUNOTHERAPY AGAINST GLIOBLASTOMA Neuro-Oncology. 19: vi243-vi244. DOI: 10.1093/Neuonc/Nox168.994 |
0.772 |
|
2017 |
Theruvath J, Heitzeneder S, Majzner R, Cui K, Nellan A, Graef CM, Cheshier SH, Mackall C, Mitra SS. IMMU-45. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON MEDULLOBLASTOMA AND PROVES TO BE A PROMISING CANDIDATE FOR CAR T CELL IMMUNOTHERAPY Neuro-Oncology. 19: vi122-vi122. DOI: 10.1093/Neuonc/Nox168.503 |
0.557 |
|
2017 |
Gholamin S, Esparza R, Cheshier S, Mitra S. TRTH-32. COMBINATION IMMUNOTHERAPY TO ACTIVATE THE INNATE IMMUNE MICROENVIRONMENT AGAINST PEDIATRIC BRAIN TUMORS Neuro-Oncology. 19: iv58-iv59. DOI: 10.1093/Neuonc/Nox083.242 |
0.758 |
|
2017 |
Theruvath J, Heitzeneder S, Majzner R, Moritz Graef C, Cui K, Nellan A, H Cheshier S, Mackall C, Mitra S. IMMU-07. CHECKPOINT MOLECULE B7-H3 IS HIGHLY EXPRESSED ON MEDULLOBLASTOMA AND PROVES TO BE A PROMISING CANDIDATE FOR CAR T CELL IMMUNOTHERAPY Neuro-Oncology. 19: iv28-iv29. DOI: 10.1093/Neuonc/Nox083.117 |
0.368 |
|
2016 |
Assad Kahn S, Costa SL, Gholamin S, Nitta RT, Dubois LG, Fève M, Zeniou M, Coelho PL, El-Habr E, Cadusseau J, Varlet P, Mitra SS, Devaux B, Kilhoffer MC, Cheshier SH, et al. The anti-hypertensive drug prazosin inhibits glioblastoma growth via the PKCδ-dependent inhibition of the AKT pathway. Embo Molecular Medicine. 8: 511-526. PMID 27138566 DOI: 10.15252/Emmm.201505421 |
0.729 |
|
2016 |
Zhang M, Hutter G, Kahn SA, Azad TD, Gholamin S, Xu CY, Liu J, Achrol AS, Richard C, Sommerkamp P, Schoen MK, McCracken MN, Majeti R, Weissman I, Mitra SS, et al. Anti-CD47 Treatment Stimulates Phagocytosis of Glioblastoma by M1 and M2 Polarized Macrophages and Promotes M1 Polarized Macrophages In Vivo. Plos One. 11: e0153550. PMID 27092773 DOI: 10.1371/Journal.Pone.0153550 |
0.772 |
|
2016 |
Singh SK, Garg N, Manornajan B, Bakhshinyan D, Venugopal C, Hallett R, Wang KX, Ramaswamy V, Cho Y, Mitra S, Kaplan D, Davis T, Taylor M. Abstract 2475: Bmi1 is a therapeutic target in recurrent medulloblastoma Cancer Research. 76: 2475-2475. DOI: 10.1158/1538-7445.Am2016-2475 |
0.386 |
|
2016 |
Kahn SA, Wang X, Nitta R, Gholamin S, Ramaswamy V, Azad T, Sahoo D, Esparza R, Chu P, Fisher P, Vogel H, Li G, Cho Y, Taylor M, Mitra S, et al. MB-16NOTCH1 PROMOTES GROUP 3 MEDULLOBLASTOMA METASTASIS, INITIATION AND SELF-RENEWAL Neuro-Oncology. 18: iii100.1-iii100. DOI: 10.1093/Neuonc/Now076.14 |
0.757 |
|
2016 |
Mitra S, Gholamin S, Feroze A, Weissman I, Cheshier S. HG-98IDENTIFICATION OF THE PRE-MALIGNANT CELL OF ORIGIN IN PEDIATRIC GLIOBLASTOMA MULTIFORME Neuro-Oncology. 18: iii71.2-iii71. DOI: 10.1093/Neuonc/Now073.94 |
0.781 |
|
2015 |
Mitra SS, Feroze AH, Gholamin S, Richard C, Esparza R, Zhang M, Azad TD, Alrfaei B, Kahn SA, Hutter G, Guzman R, Creasey GH, Plant GW, Weissman IL, Edwards MS, et al. Neural Placode Tissue Derived From Myelomeningocele Repair Serves as a Viable Source of Oligodendrocyte Progenitor Cells. Neurosurgery. PMID 26225855 DOI: 10.1227/Neu.0000000000000918 |
0.759 |
|
2015 |
Venkatesh HS, Johung TB, Caretti V, Noll A, Tang Y, Nagaraja S, Gibson EM, Mount CW, Polepalli J, Mitra SS, Woo PJ, Malenka RC, Vogel H, Bredel M, Mallick P, et al. Neuronal Activity Promotes Glioma Growth through Neuroligin-3 Secretion. Cell. 161: 803-16. PMID 25913192 DOI: 10.1016/J.Cell.2015.04.012 |
0.323 |
|
2015 |
Esparza R, Azad TD, Feroze AH, Mitra SS, Cheshier SH. Glioblastoma stem cells and stem cell-targeting immunotherapies. Journal of Neuro-Oncology. 123: 449-57. PMID 25682090 DOI: 10.1007/S11060-015-1729-X |
0.628 |
|
2015 |
Feng M, Chen JY, Weissman-Tsukamoto R, Volkmer JP, Ho PY, McKenna KM, Cheshier S, Zhang M, Guo N, Gip P, Mitra SS, Weissman IL. Macrophages eat cancer cells using their own calreticulin as a guide: roles of TLR and Btk. Proceedings of the National Academy of Sciences of the United States of America. 112: 2145-50. PMID 25646432 DOI: 10.1073/Pnas.1424907112 |
0.721 |
|
2015 |
Nitta RT, Gholamin S, Feroze AH, Agarwal M, Cheshier SH, Mitra SS, Li G. Casein kinase 2α regulates glioblastoma brain tumor-initiating cell growth through the β-catenin pathway. Oncogene. 34: 3688-99. PMID 25241897 DOI: 10.1038/Onc.2014.299 |
0.787 |
|
2015 |
Mitra SS, Gholamin S, Sinha R, Morganti RM, Weissman I, Cheshier SH. Abstract A11: Identification of the premalignant cell of origin in human glioblastoma multiforme Brain. 75. DOI: 10.1158/1538-7445.Brain15-A11 |
0.814 |
|
2015 |
Zhu H, Yang N, Leiss L, Rygh CB, Mitra SS, Cheshier SH, Huang B, Bjerkvig R, Enger PØ, Weissman IL, Li X, Wang J. Abstract 1331: Targeting CD47 triggers macrophage-dependent brain tumor destruction in a clinical relevant model Cancer Research. 75: 1331-1331. DOI: 10.1158/1538-7445.Am2015-1331 |
0.737 |
|
2015 |
Gholamin S, Mitra S, Esparza R, Liu J, Feroze A, Cho YJ, Zhang M, Vogel H, Edwards M, Weissman I, Cheshier S. IMPS-26HARNESSING THE MYELOID CHECKPOINT CD47-SIRPa AXIS AGAINST ADULT AND PEDIATRIC MALIGNANT BRAIN TUMORS: A NOVEL IMMUNOTHERAPEUTIC MODALITY Neuro-Oncology. 17: v118.4-v118. DOI: 10.1093/Neuonc/Nov217.25 |
0.815 |
|
2015 |
Kahn S, Nitta R, Wang K, Gholamin S, Azad T, Zhang M, Cho Y, Taylor M, Mitra S, Weissman I, Cheshier S. MB-01 * NOTCH1 PROMOTES MYC MEDULLOBLASTOMA METASTASIS, INITIATION AND MAINTENANCE Neuro-Oncology. 17: iii19-iii20. DOI: 10.1093/Neuonc/Nov061.77 |
0.808 |
|
2015 |
Gholamin S, Kahn SA, Esparza R, Hutter G, Feroze A, Weissman IL, Mitra SS, Cheshier SH. PM-08 * A HUMANIZED CO-TRANSPLANT XENOGRAFT MOUSE MODEL, TO STUDY TOXICITY OF DRUGS TARGETED AGAINST PEDIATRIC BRAIN TUMORS Neuro-Oncology. 17: iii32-iii32. DOI: 10.1093/Neuonc/Nov061.130 |
0.794 |
|
2014 |
Tang Y, Gholamin S, Schubert S, Willardson MI, Lee A, Bandopadhayay P, Bergthold G, Masoud S, Nguyen B, Vue N, Balansay B, Yu F, Oh S, Woo P, Chen S, ... ... Mitra S, et al. Epigenetic targeting of Hedgehog pathway transcriptional output through BET bromodomain inhibition. Nature Medicine. 20: 732-40. PMID 24973920 DOI: 10.1038/Nm.3613 |
0.747 |
|
2014 |
Emlet DR, Gupta P, Holgado-Madruga M, Del Vecchio CA, Mitra SS, Han SY, Li G, Jensen KC, Vogel H, Xu LW, Skirboll SS, Wong AJ. Targeting a glioblastoma cancer stem-cell population defined by EGF receptor variant III. Cancer Research. 74: 1238-49. PMID 24366881 DOI: 10.1158/0008-5472.Can-13-1407 |
0.432 |
|
2014 |
Bandopadhayay P, Bergthold G, Nguyen B, Schubert S, Gholamin S, Tang Y, Bolin S, Schumacher SE, Zeid R, Masoud S, Yu F, Vue N, Gibson WJ, Paolella BR, Mitra SS, et al. BET bromodomain inhibition of MYC-amplified medulloblastoma. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. 20: 912-25. PMID 24297863 DOI: 10.1158/1078-0432.Ccr-13-2281 |
0.741 |
|
2014 |
Mitra SS, Gholamin S, Volkmer J, Feroze A, Liu J, Achrol A, Wang L, Sayles L, Zhang M, Sakamoto K, Monje-Deisseroth M, Cho Y, Sweet-Cordero A, Majeti R, Cheshier S, et al. Abstract PR12: Overcoming immune evasion in pediatric hematologic and solid tumor malignancies: A preclinical study using a humanized anti-CD47 antibody Cancer Research. 74. DOI: 10.1158/1538-7445.Pedcan-Pr12 |
0.822 |
|
2014 |
Feroze AH, Lee K, Gholamin S, Wu Z, Weissman I, Lu B, Mitra SS, Cheshier S. Abstract LB-207: mTORC2/Akt signaling is modulated by noncanonical mitochondrial Notch1/PINK1 interaction in myc-amplified medulloblastoma tumorigenesis Cancer Research. 74. DOI: 10.1158/1538-7445.Am2014-Lb-207 |
0.804 |
|
2014 |
Kahn SA, Gholamin S, Zhang M, Nitta R, Weissman I, Mitra S, Cheshier S. Abstract 4041: Involvement of Notch1 signaling pathway in medulloblastoma metastasis Cancer Research. 74: 4041-4041. DOI: 10.1158/1538-7445.Am2014-4041 |
0.81 |
|
2014 |
Feroze A, Lee K, Alrfaei B, Gholamin S, Azad T, Mitra S, Lu B, Cheshier S. CS-07 * mTORC2/Akt SIGNALING IS MODULATED BY NONCANONICAL MITOCHONDRIAL NOTCH-PINK1 INTERACTION IN MEDULLOBLASTOMA (GROUP III) TUMORIGENESIS Neuro-Oncology. 16: v52-v52. DOI: 10.1093/Neuonc/Nou242.7 |
0.752 |
|
2013 |
Lee KS, Wu Z, Song Y, Mitra SS, Feroze AH, Cheshier SH, Lu B. Roles of PINK1, mTORC2, and mitochondria in preserving brain tumor-forming stem cells in a noncanonical Notch signaling pathway. Genes & Development. 27: 2642-7. PMID 24352421 DOI: 10.1101/Gad.225169.113 |
0.598 |
|
2013 |
Adorno M, Sikandar S, Mitra SS, Kuo A, Nicolis Di Robilant B, Haro-Acosta V, Ouadah Y, Quarta M, Rodriguez J, Qian D, Reddy VM, Cheshier S, Garner CC, Clarke MF. Usp16 contributes to somatic stem-cell defects in Down's syndrome. Nature. 501: 380-4. PMID 24025767 DOI: 10.1038/nature12530 |
0.528 |
|
2013 |
Gholamin S, Feroze AH, Mitra SS, Kahn SA, Cheshier SH. Establishment of Stereotactic Orthotopic Brain Tumor Xenografts in Mice: Technical Report Cureus. DOI: 10.7759/Cureus.150 |
0.791 |
|
2013 |
Gholamin S, Mitra SS, Richard CE, Achrol A, Kong D, Shin JJ, Monje-Deisseroth M, Cho Y, Weissman I, Cheshier SH. Abstract 5218: Development of Anti-CD47 therapy for pediatric brain tumors. Cancer Research. 73: 5218-5218. DOI: 10.1158/1538-7445.Am2013-5218 |
0.817 |
|
2013 |
Mitra SS, Gholamin S, Feroze A, Cheshier SH, Weissman IL. Abstract 5007: Delineating human fetal CNS stem cell hierarchy reveals a progenitor cell of origin for human Gliobastoma Multiforme. Cancer Research. 73: 5007-5007. DOI: 10.1158/1538-7445.Am2013-5007 |
0.815 |
|
2013 |
Emlet DR, Vecchio CD, Gupta P, Mitra S, Han S, Holgado-Madruga M, Li G, Jensen K, Vogel H, Skirboll S, Wong AJ. Abstract 3733: Defining and targeting a Glioblastoma cancer stem cell population with EGF Receptor Variant III. Cancer Research. 73: 3733-3733. DOI: 10.1158/1538-7445.Am2013-3733 |
0.409 |
|
2013 |
Adachi K, Sasaki H, Nagahisa S, Yoshida K, Hattori N, Nishiyama Y, Kawase T, Hasegawa M, Abe M, Hirose Y, Alentorn A, Marie Y, Poggioli S, Alshehhi H, Boisselier B, ... ... Mitra S, et al. OMICS AND PROGNSTIC MARKERS Neuro-Oncology. 15: iii136-iii155. DOI: 10.1093/Neuonc/Not183 |
0.7 |
|
2013 |
Campian J, Gladstone D, Ambady P, Ye X, King K, Borrello I, Petrik S, Golightly M, Holdhoff M, Grossman S, Bhardwaj R, Chakravadhanula M, Ozols V, Georges J, Carlson E, ... ... Mitra SS, et al. IMMUNOTHERAPY/BIOLOGICAL THERAPIES Neuro-Oncology. 15: iii68-iii74. DOI: 10.1093/Neuonc/Not178 |
0.745 |
|
2013 |
Agarwal M, Nitta R, Dovat S, Li G, Arita H, Narita Y, Fukushima S, Tateishi K, Matsushita Y, Yoshida A, Miyakita Y, Ohno M, Collins VP, Kawahara N, Shibui S, ... ... Mitra S, et al. CELL BIOLOGY AND SIGNALING Neuro-Oncology. 15: iii12-iii31. DOI: 10.1093/Neuonc/Not174 |
0.768 |
|
2012 |
Mitra SS, Xu J, Nicholson BJ. Coregulation of multiple signaling mechanisms in pp60v-Src-induced closure of Cx43 gap junction channels. The Journal of Membrane Biology. 245: 495-506. PMID 22965738 DOI: 10.1007/S00232-012-9500-0 |
0.567 |
|
2012 |
Willingham SB, Volkmer JP, Gentles AJ, Sahoo D, Dalerba P, Mitra SS, Wang J, Contreras-Trujillo H, Martin R, Cohen JD, Lovelace P, Scheeren FA, Chao MP, Weiskopf K, Tang C, et al. The CD47-signal regulatory protein alpha (SIRPa) interaction is a therapeutic target for human solid tumors. Proceedings of the National Academy of Sciences of the United States of America. 109: 6662-7. PMID 22451913 DOI: 10.1073/Pnas.1121623109 |
0.637 |
|
2012 |
Li G, Mitra SS, Monje M, Henrich KN, Bangs CD, Nitta RT, Wong AJ. Expression of epidermal growth factor variant III (EGFRvIII) in pediatric diffuse intrinsic pontine gliomas. Journal of Neuro-Oncology. 108: 395-402. PMID 22382786 DOI: 10.1007/S11060-012-0842-3 |
0.354 |
|
2012 |
Kijima N, Hosen N, Kagawa N, Hashimoto N, Chiba Y, Kinoshita M, Sugiyama H, Yoshimine T, Kim YZ, Kim KH, Lee EH, Hu B, Sim H, Mohan N, Agudelo-Garcia P, ... ... Mitra S, et al. LAB-CELL BIOLOGY AND SIGNALING Neuro-Oncology. 14: vi7-vi20. DOI: 10.1093/Neuonc/Nos220 |
0.31 |
|
2011 |
Monje M, Mitra SS, Freret ME, Raveh TB, Kim J, Masek M, Attema JL, Li G, Haddix T, Edwards MS, Fisher PG, Weissman IL, Rowitch DH, Vogel H, Wong AJ, et al. Hedgehog-responsive candidate cell of origin for diffuse intrinsic pontine glioma. Proceedings of the National Academy of Sciences of the United States of America. 108: 4453-8. PMID 21368213 DOI: 10.1073/Pnas.1101657108 |
0.62 |
|
2011 |
Nitta RT, Del Vecchio CA, Chu AH, Mitra SS, Godwin AK, Wong AJ. The role of the c-Jun N-terminal kinase 2-α-isoform in non-small cell lung carcinoma tumorigenesis. Oncogene. 30: 234-44. PMID 20871632 DOI: 10.1038/Onc.2010.414 |
0.364 |
|
2010 |
Gupta P, Han SY, Holgado-Madruga M, Mitra SS, Li G, Nitta RT, Wong AJ. Development of an EGFRvIII specific recombinant antibody. Bmc Biotechnology. 10: 72. PMID 20925961 DOI: 10.1186/1472-6750-10-72 |
0.356 |
|
2010 |
Li G, Mitra S, Karamchandani J, Edwards MS, Wong AJ. Pineal parenchymal tumor of intermediate differentiation: clinicopathological report and analysis of epidermal growth factor receptor variant III expression. Neurosurgery. 66: 963-8; discussion 96. PMID 20404701 DOI: 10.1227/01.Neu.0000367726.49003.F1 |
0.349 |
|
2010 |
Li G, Mitra S, Wong AJ. The epidermal growth factor variant III peptide vaccine for treatment of malignant gliomas. Neurosurgery Clinics of North America. 21: 87-93. PMID 19944969 DOI: 10.1016/J.Nec.2009.08.004 |
0.324 |
|
2010 |
Mitra S, Li G, Harsh GR. Passive antibody-mediated immunotherapy for the treatment of malignant gliomas. Neurosurgery Clinics of North America. 21: 67-76. PMID 19944967 DOI: 10.1016/J.Nec.2009.08.010 |
0.399 |
|
2010 |
Nitta RT, Chu A, Mitra S, Godwin A, Wong A. Abstract 310: The role of c-Jun N-terminal kinase 2alpha in non-small cell lung carcinoma tumorigenesis Cancer Research. 70: 310-310. DOI: 10.1158/1538-7445.Am10-310 |
0.365 |
|
2009 |
Wong A, Mitra S, Gupta P. Targeting brain tumor stem cells using a bispecific antibody directed against CD133+ and EGFRvIII. Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology. 27: 2022. PMID 27964602 DOI: 10.1200/Jco.2009.27.15_Suppl.2022 |
0.422 |
|
Show low-probability matches. |